CONVERTIBLE LOANS (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
May 21, 2024 |
Jan. 01, 2024 |
Mar. 27, 2023 |
Oct. 31, 2024 |
Jan. 31, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Sep. 05, 2024 |
Jul. 14, 2024 |
May 22, 2024 |
Apr. 23, 2024 |
Apr. 18, 2024 |
Mar. 07, 2024 |
Feb. 23, 2023 |
|
| Debt Instrument [Line Items] | ||||||||||||||
| Common stock issued | 5,199,963 | 3,216,363 | ||||||||||||
| Number of securities called by warrants or rights | 20,000 | 50,000 | 50,000 | 50,000 | ||||||||||
| Exercise price of warrants | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.3 | $ 10.90 | |||||||
| Loss on extinguishment of debt | $ (5,422,000) | $ (283,000) | ||||||||||||
| Offshore Investor [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Conversion rate | $ 0.85 | |||||||||||||
| Proceeds from issuance of warrants | $ 840,000 | |||||||||||||
| Share price | $ 0.85 | |||||||||||||
| Koligo Therapeutics Inc [Member] | Lender [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Debt instrument maturity date | Jan. 01, 2024 | |||||||||||||
| Original principal amount | $ 5,000,000 | |||||||||||||
| Interest rate | 8.00% | |||||||||||||
| Koligo Therapeutics Inc [Member] | Borrower [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Debt instrument conversion | If prior to December 31, 2023, the Borrower issues equity securities (“Equity Securities”) in a transaction or series of related transactions resulting in aggregate gross proceeds to the Borrower of at least $5,000 (excluding conversion of the Loan Amount) (a “Qualified Financing”), then the outstanding principal amount of the Loan Amount, and any and all accrued but unpaid interest thereon (collectively, the “Outstanding Amount”), will automatically convert into such Equity Securities issued pursuant to the Qualified Financing at a price per share equal to fifty percent (50%) of the price per share paid for each share of the Equity Securities purchased for cash by the investors in the Qualified Financing (the “Mandatory Conversion”). The per share price for the Mandatory Conversion shall be calculated on a fully diluted basis (including equity underlying all outstanding options, warrants, and other convertible securities, but excluding the Equity Securities issuable upon the Mandatory Conversion). | |||||||||||||
| Debt Exchange Agreements [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Conversion rate | $ 8.5 | |||||||||||||
| Debt instrument maturity date | Dec. 31, 2024 | Dec. 31, 2026 | ||||||||||||
| Number of securities called by warrants or rights | 36,000 | 84,000 | ||||||||||||
| Exercise price of warrants | $ 8.5 | $ 8.5 | ||||||||||||
| Debt Exchange Agreements [Member] | Three Convertible Debt Holders [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Outstanding principal and accrued interest | $ 16,007,000 | |||||||||||||
| Number of shares issued | 1,577,695 | |||||||||||||
| Common stock issued | 1,577,694 | |||||||||||||
| Outstanding principal | $ 14,784,000 | |||||||||||||
| Debt conversion expense | $ 4,304,000 | |||||||||||||
| Debt Exchange Agreements [Member] | Three Convertible Debt Holders [Member] | Maximum [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Conversion rate | $ 25.0 | |||||||||||||
| Debt Exchange Agreements [Member] | Three Convertible Debt Holders [Member] | Minimum [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Conversion rate | $ 10.3 | |||||||||||||
| Loan Agreement [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Loss on extinguishment of debt | $ 5,280 | $ 141,000 | ||||||||||||
| Convertible Loan Agreements [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Convertible subordinated debt | $ 773,000 | |||||||||||||
| Convertible Loan Agreements [Member] | Lender [Member] | ||||||||||||||
| Debt Instrument [Line Items] | ||||||||||||||
| Debt instrument maturity date | Jan. 31, 2026 | |||||||||||||
| Original principal amount | $ 1,500,000 | |||||||||||||
| Interest rate | 10.00% | |||||||||||||